Tipiracil Hydrochlorideis the combination of an antineoplastic pyrimidine analog (trifluridine) with an inhibitor of its metabolism (tipiracil) that is used in the therapy of refractory, metastatic colorectal cancer. Trifluridine/tipiracil is associated with a low rate of transient serum enzyme elevations during therapy but has not been implicated in cases of clinically apparent acute liver injury with jaundice.
Trifluridine is a fluorinated thymidine analog with potential antineoplastic activity. Trifluridine is incorporated into DNA and inhibits thymidylate synthase, resulting in the inhibition of DNA synthesis, inhibition of protein synthesis, and apoptosis. This agent also exhibits antiviral activity. (NCI04)
Trifluridine is a pyrimidine 2′-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis. It has a role as an antiviral drug, an antimetabolite, an EC 2.1.1.45 (thymidylate synthase) inhibitor, and an antineoplastic agent. It is a nucleoside analog, an organofluorine compound, and a pyrimidine 2′-deoxyribonucleoside.
Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to idoxuridine. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to the herpes simplex virus. It displays effective antiviral activity against Herpes simplex virus types 1 and 2 [rx].
The combination product of trifluridine with tipiracil marketed as Lonsurf has been approved in Japan, the United States, and the European Union for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. In anticancer therapy, trifluridine acts as a thymidine-based nucleoside metabolic inhibitor that gets incorporated into the DNA of cancer cells following cell uptake to aberrate DNA function during cell replication [rx].
Mechanism of Action
The mechanism of action of trifluridine as an antiviral agent has not been fully elucidated but appears to involve the inhibition of viral replication. Trifluridine gets incorporated into viral DNA during replication, which leads to the formation of defective proteins and an increased mutation rate. Trifluridine also mediates antineoplastic activities via this mechanism; following uptake into cancer cells, trifluridine is rapidly phosphorylated by thymidine kinase to its active monophosphate form. Subsequent phosphorylation produces trifluridine triphosphate, which is readily incorporated into the DNA of tumor cells in place of thymidine bases to perturb DNA function, DNA synthesis, and tumor cell proliferation. As trifluridine is subject to rapid degradation by TPase and readily metabolized by a first-pass effect following oral administration, tipiracil is added to the antineoplastic combination product as an inhibitor of TPase to increase the bioavailability of trifluridine. Trifluridine monophosphate also reversibly inhibits thymidylate synthetase (TS), an enzyme that is necessary for DNA synthesis and whose levels are shown to be elevated in different cancer cell lines. Up-regulation of the expression of the TS enzyme may also lead to resistance to antineoplastic therapies, such as 5-fluorouracil (5-FU). However, this inhibitory effect is not considered to be sufficient enough to fully contribute to the cytotoxicity in cancer cells.
or
Trifluridine is a fluorinated pyrimidine nucleoside with in vitro and in vivo activity against herpes simplex virus, types 1 and 2, and vaccinia virus. Some strains of adenovirus are also inhibited in vitro. …Trifluridine interferes with DNA synthesis in cultured mammalian cells. However, its antiviral mechanism of action is not completely known
Trifluridine exhibits an antiviral effect against herpes simplex virus, types 1 and 2, and vaccinia virus both in vitro and in vivo. Some strains of adenovirus that contribute to the pathology of keratoconjunctivitis were shown to be susceptible to trifluridine _in vitro_. While there is evidence from a study that cross-resistance may develop between trifluridine and [idoxuridine] or [vidarabine], trifluridine was shown to be effective in treating dendritic ulcers in patients with herpetic keratitis who are unresponsive to [idoxuridine] or [vidarabine] based on the results from masked comparative trials. In nonclinical studies, trifluridine/tipiracil hydrochloride demonstrated antitumor activity against both 5-fluorouracil (5-FU) sensitive and resistant colorectal cancer cell lines. The cytotoxic activity of trifluridine and tipiracil against several human tumor xenografts show a high correlation with the amount of trifluridine incorporated into DNA, indicating that the primary mechanism of action of trifluridine involves the direct incorporation into the cancer cell DNA. Trifluridine and tipiracil demonstrated anti-tumor activity against KRAS wild-type and mutant human colorectal cancer xenografts in mice. In clinical studies comprised of patients with previously treated metastatic colorectal cancer, treatment of trifluridine in combination with tipiracil in addition to best supportive care over a 5- or 7-month period resulted in increased progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) compared to placebo. In an open-label study, administration of trifluridine at the recommended dosage in patients with advanced solid tumors had no clinically relevant effect on QT/QTc prolongation compared with placebo. Two out of 48 patients displayed had QTc greater than 500 msec and 1 of 42 patients (2.4%) had a QTc increase from baseline greater than 60 msec.
Indications
- Trifluridine is used for the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus types 1 and 2 in ophthalmic solutions. Trifluridine, in combination with [tipiracil], is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin– and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
- This combination use is also used to treat metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, platinum, either a taxane or irinotecan and if appropriate, HER2/neu-targeted therapy.
- Trifluridine is a nucleoside metabolic inhibitor used to treat keratoconjunctivitis and epithelial keratitis caused by simplex virus, and as a part of chemotherapy for certain types of metastatic gastrointestinal cancers.
- Trifluridine/tipiracil is the combination of an antineoplastic pyrimidine analog (trifluridine) with an inhibitor of its metabolism (tipiracil) that is used in the therapy of refractory, metastatic colorectal cancer.
- Trifluridine Ophthalmic Solution is indicated for the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus types 1 and 2.
- Trifluridine is also effective in the treatment of epithelial keratitis that has not responded clinically to the topical administration of idoxuridine or when ocular toxicity or hypersensitivity to idoxuridine has occurred. In a smaller number of patients found to be resistant to topical vidarabine, trifluridine was also effective.
- Trifluridine, in combination with tipiracil, is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. This combination use is also used to treat metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, platinum, either a taxane or irinotecan and if appropriate, HER2/neu-targeted therapy.[rx]
- Metastatic Colorectal Cancer (CRC)
- Metastatic Gastric Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Primary keratoconjunctivitis caused by herpes simplex virus type 2
- Recurrent epithelial keratitis caused by herpes simplex 2
- Vaccinia infection in the cornea and conjunctiva
- Vaccinia virus ophthalmic infections
Use in Cancer
Trifluridine and tipiracil hydrochloride are approved to treat:
- Colorectal cancer that has metastasized (spread to other parts of the body). It is used in adults who have already been treated with a fluoropyrimidine, oxaliplatin, irinotecan hydrochloride, and a VEGF inhibitor. Patients whose cancer has the wild-type KRAS gene should have also received an EGFR inhibitor.
- Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that has metastasized. It is used in adults who have already received at least two treatments with fluoropyrimidine and platinum chemotherapy and either a taxane or irinotecan and, in some cases, HER2/neu-targeted therapy.
Trifluridine and tipiracil hydrochloride is also being studied in the treatment of other types of cancer.
Contraindications
- Trifluridine ophthalmic solution is contraindicated for patients who develop hypersensitivity reactions or chemical intolerance to trifluridine.
- Continuous administration of trifluridine for periods exceeding 21 days should be avoided because of potential ocular toxicity.[32394] Punctate lesions in the corneal epithelium are clinical manifestations of trifluridine cytotoxicity. Upon discontinuation, toxic changes to the surface of the eye are generally reversible
- Safe and effective use of trifluridine ophthalmic solution has not been established in neonates, infants, and children below six years of age. No overall differences in safety or effectiveness have been observed between young adult and geriatric patients.
Dosage
The usual recommended adult dose of trifluridine eye drops is 1 drop into the affected eye(s) (on the cornea) every 2 hours while awake (up to a maximum of 9 drops per day).
This dose is continued until the eye lesion heals, usually within 7 to 14 days. Then, the usual dose is 1 drop into the affected eye(s) every 4 hours (up to a maximum of 5 drops per day) while awake for 7 days. The medication should not be used for longer than 21 days. If no improvement is seen in 7 days, or if the lesion has not healed within 14 days, see your doctor.
The bottle is only partially full to provide proper drop control.
- First, wash your hands. Then tilt the head back and pull the lower eyelid away from the eye to form a pouch. Drop the medicine into the pouch and gently close your eyes. Do not blink. Keep the eyes closed for 1 or 2 minutes to allow the medicine to come into contact with the infection.
- If you think you did not get the drop of medicine into your eye properly, use another drop.
- To keep the medicine as germ-free as possible, do not touch the applicator tip to any surface (including the eye). Also, keep the container tightly closed.
Do not use this medicine more often or for a longer time than your doctor ordered. To do so may cause problems in the eyes. If you have any questions about this, check with your doctor. To help clear up your infection completely, keep using this medicine for the full time of treatment, even if your symptoms have disappeared. Do not miss any doses.
Dosing
The dose of this medicine will be different for different patients. Follow your doctor’s orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
- For ophthalmic solution dosage forms:
- For viral eye infection:
- Adults and children 6 years of age and older—One drop every two hours while you are awake. After healing has occurred, the dose may be reduced for seven more days to one drop every four hours (at least 5 doses a day) while you are awake.
- Children up to 6 years of age—Use and dose must be determined by your doctor.
- For viral eye infection:
Missed Dose
If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.
Side Effects
The Most Common
- hair loss
- change in the way things taste
- loss of appetite
- mouth sores or swelling inside the mouth
- lack of energy
- excessive tiredness
- fever, body aches, chills, or other signs of infection
- nausea, vomiting, diarrhea, or abdominal pain that is severe or does not go away
- weakness or shortness of breath when exercising
- pale skin
- chest pain
- pain with deep breathing
- coughing up blood
- unusual bleeding or bruising
More Common
- Blurred vision or other change in vision
- dryness of eye
- irritation of eye
- itching, redness, swelling, or other sign of irritation not present before use of this medicine
- burning or stinging
- mild irritation of the eye
- swelling and redness of the eyelid
- itching, redness, swelling, or other sign of irritation not present before use of this medication
- signs of an allergic reaction (e.g., skin itching, rash, redness, swelling, or hives)
Rare
- Blurred vision or other change in vision
- dryness of eye
- irritation of eye
- itching, redness, swelling, or other sign of irritation not present before use of this medicine
Drug Interaction
| DRUG | INTERACTION |
|---|---|
| Abacavir | Trifluridine may decrease the excretion rate of Abacavir which could result in a higher serum level. |
| Abatacept | The risk or severity of adverse effects can be increased when Trifluridine is combined with Abatacept. |
| Aceclofenac | Aceclofenac may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Acemetacin | Acemetacin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Acetaminophen | Acetaminophen may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Acetazolamide | Acetazolamide may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Acetylsalicylic acid | The excretion of Trifluridine can be decreased when combined with Acetylsalicylic acid. |
| Aclidinium | Trifluridine may decrease the excretion rate of Aclidinium which could result in a higher serum level. |
| Acrivastine | Trifluridine may decrease the excretion rate of Acrivastine which could result in a higher serum level. |
| Acyclovir | The excretion of Trifluridine can be decreased when combined with Acyclovir. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Trifluridine. |
| Adefovir dipivoxil | Adefovir dipivoxil may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Adenovirus type | The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Trifluridine. |
| Albutrepenonacog | Trifluridine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level. |
| Alclofenac | Alclofenac may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Trifluridine. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Trifluridine. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trifluridine. |
| Allogeneic proce | The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Trifluridine. |
| Allopurinol | Trifluridine may decrease the excretion rate of Allopurinol which could result in a higher serum level. |
| Almasilate | Trifluridine may decrease the excretion rate of Almasilate which could result in a higher serum level. |
| Almotriptan | Trifluridine may decrease the excretion rate of Almotriptan which could result in a higher serum level. |
| Alogliptin | Trifluridine may decrease the excretion rate of Alogliptin which could result in a higher serum level. |
| Alprazolam | Alprazolam may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Alprostadil | The excretion of Alprostadil can be decreased when combined with Trifluridine. |
| Altretamine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Altretamine. |
| Amantadine | Trifluridine may decrease the excretion rate of Amantadine which could result in a higher serum level. |
| Amikacin | Trifluridine may decrease the excretion rate of Amikacin which could result in a higher serum level. |
| Amiloride | Amiloride may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Aminohippuric acid | The excretion of Trifluridine can be decreased when combined with Aminohippuric acid. |
| Aminophenazone | Aminophenazone may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Amitriptyline | Amitriptyline may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Ammonium chloride | Trifluridine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level. |
| Amoxicillin | Trifluridine may decrease the excretion rate of Amoxicillin which could result in a higher serum level. |
| Amphetamine | Amphetamine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Amphotericin B | Amphotericin B may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Ampicillin | Ampicillin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Amrinone | Trifluridine may decrease the excretion rate of Amrinone which could result in a higher serum level. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Trifluridine. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Trifluridine. |
| Ancestim | Trifluridine may decrease the excretion rate of Ancestim which could result in a higher serum level. |
| Anifrolumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Anifrolumab. |
| Anthrax immune | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Trifluridine. |
| Anthrax vaccine | The risk or severity of infection can be increased when Anthrax vaccine is combined with Trifluridine. |
| Antihemophilic | Trifluridine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level. |
| Antilymphocyte i | The risk or severity of adverse effects can be increased when Trifluridine is combined with Antilymphocyte immunoglobulin (horse). |
| Antipyrine | Antipyrine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Antithrombin III | Trifluridine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level. |
| Antithymocyte im | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trifluridine. |
| Antrafenine | Antrafenine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Apalutamide | The excretion of Trifluridine can be decreased when combined with Apalutamide. |
| Apremilast | The risk or severity of adverse effects can be increased when Trifluridine is combined with Apremilast. |
| Arformoterol | Trifluridine may decrease the excretion rate of Arformoterol which could result in a higher serum level. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Trifluridine is combined with Arsenic trioxide. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Articaine. |
| A COVID-19 Vacc | The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Trifluridine. |
| Ataluren | The excretion of Trifluridine can be decreased when combined with Ataluren. |
| Atazanavir | Atazanavir may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Atomoxetine | Atomoxetine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Auranofin | Trifluridine may decrease the excretion rate of Auranofin which could result in a higher serum level. |
| Aurothioglucose | Trifluridine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level. |
| Avatrombopag | The excretion of Trifluridine can be decreased when combined with Avatrombopag. |
| Azacitidine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Azacitidine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Azathioprine. |
| Azelaic acid | Trifluridine may decrease the excretion rate of Azelaic acid which could result in a higher serum level. |
| Aztreonam | Aztreonam may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Bacillus calmette | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Trifluridine. |
| Bacillus | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Trifluridine. |
| Bacillus cal | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Trifluridine. |
| Bacitracin | Bacitracin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Baclofen | Baclofen may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Balsalazide | Balsalazide may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Baricitinib | The risk or severity of adverse effects can be increased when Trifluridine is combined with Baricitinib. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Trifluridine. |
| BCG vaccine | The risk or severity of infection can be increased when BCG vaccine is combined with Trifluridine. |
| Beclomethasone di | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Trifluridine. |
| Belatacept | The risk or severity of adverse effects can be increased when Trifluridine is combined with Belatacept. |
| Belimumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Belimumab. |
| Belinostat | The risk or severity of adverse effects can be increased when Trifluridine is combined with Belinostat. |
| Belumosudil | The risk or severity of adverse effects can be increased when Trifluridine is combined with Belumosudil. |
| Bendamustine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Bendamustine. |
| Bendroflumethiaz | Bendroflumethiazide may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Benorilate | Benorilate may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Benoxaprofen | Benoxaprofen may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Benserazide | Trifluridine may decrease the excretion rate of Benserazide which could result in a higher serum level. |
| Benzatropine | Benzatropine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Benznidazole | Trifluridine may decrease the excretion rate of Benznidazole which could result in a higher serum level. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Benzocaine. |
| Benzoic acid | The excretion of Trifluridine can be decreased when combined with Benzoic acid. |
| Benzthiazide | Benzthiazide may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Benzydamine | Benzydamine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Benzyl alcohol. |
| Benzylpenicillin | The excretion of Trifluridine can be decreased when combined with Benzylpenicillin. |
| Bepotastine | Trifluridine may decrease the excretion rate of Bepotastine which could result in a higher serum level. |
| Betamethasone | The risk or severity of adverse effects can be increased when Trifluridine is combined with Betamethasone. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Trifluridine. |
| Bicisate | Trifluridine may decrease the excretion rate of Bicisate which could result in a higher serum level. |
| Bimekizumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Bimekizumab. |
| Bismuth subgallate | Trifluridine may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level. |
| Bisoprolol | Trifluridine may decrease the excretion rate of Bisoprolol which could result in a higher serum level. |
| Bisoxatin | Trifluridine may decrease the excretion rate of Bisoxatin which could result in a higher serum level. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Trifluridine. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Blinatumomab. |
| Bordetella pert | The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Trifluridine. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Trifluridine. |
| Bosutinib | The risk or severity of adverse effects can be increased when Trifluridine is combined with Bosutinib. |
| Brentuximab ve | The risk or severity of adverse effects can be increased when Trifluridine is combined with Brentuximab vedotin. |
| Brivaracetam | Trifluridine may decrease the excretion rate of Brivaracetam which could result in a higher serum level. |
| Brodalumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Brodalumab. |
| Bromazepam | Trifluridine may decrease the excretion rate of Bromazepam which could result in a higher serum level. |
| Bromotheophylline | Bromotheophylline may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Budesonide | The risk or severity of adverse effects can be increased when Trifluridine is combined with Budesonide. |
| Bumadizone | Bumadizone may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Bumetanide | The excretion of Trifluridine can be decreased when combined with Bumetanide. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Bupivacaine. |
| Bupropion | Trifluridine may decrease the excretion rate of Bupropion which could result in a higher serum level. |
| Buspirone | Trifluridine may decrease the excretion rate of Buspirone which could result in a higher serum level. |
| Busulfan | The risk or severity of adverse effects can be increased when Trifluridine is combined with Busulfan. |
| Butabarbital | Butabarbital may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Butacaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Butamben. |
| Cabazitaxel | The risk or severity of adverse effects can be increased when Trifluridine is combined with Cabazitaxel. |
| Cabotegravir | The excretion of Trifluridine can be decreased when combined with Cabotegravir. |
| Canagliflozin | Canagliflozin may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Canakinumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Canakinumab. |
| Canrenoic acid | Canrenoic acid may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Capecitabine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Capecitabine. |
| Capreomycin | Trifluridine may decrease the excretion rate of Capreomycin which could result in a higher serum level. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Capsaicin. |
| Captopril | The excretion of Captopril can be decreased when combined with Trifluridine. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Carbamazepine. |
| Carbenicillin | The excretion of Trifluridine can be decreased when combined with Carbenicillin. |
| Carbidopa | Carbidopa may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Carboplatin | The risk or severity of adverse effects can be increased when Trifluridine is combined with Carboplatin. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Trifluridine is combined with Carfilzomib. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Trifluridine. |
| Carprofen | Carprofen may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Caspofungin | The excretion of Trifluridine can be decreased when combined with Caspofungin. |
| Cefaclor | The excretion of Trifluridine can be decreased when combined with Cefaclor. |
| Cefadroxil | The excretion of Trifluridine can be decreased when combined with Cefadroxil. |
| Cefalotin | The excretion of Trifluridine can be decreased when combined with Cefalotin. |
| Cefamandole | The excretion of Trifluridine can be decreased when combined with Cefamandole. |
| Cefapirin | Cefapirin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cefazolin | The excretion of Trifluridine can be decreased when combined with Cefazolin. |
| Cefdinir | Trifluridine may decrease the excretion rate of Cefdinir which could result in a higher serum level. |
| Cefditoren | Cefditoren may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cefepime | Cefepime may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cefmenoxime | Cefmenoxime may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cefmetazole | Cefmetazole may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cefonicid | Cefonicid may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cefoperazone | The excretion of Trifluridine can be decreased when combined with Cefoperazone. |
| Ceforanide | Ceforanide may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cefotaxime | The excretion of Trifluridine can be decreased when combined with Cefotaxime. |
| Cefotetan | Cefotetan may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cefotiam | The excretion of Trifluridine can be decreased when combined with Cefotiam. |
| Cefoxitin | Cefoxitin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cefpiramide | Cefpiramide may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cefpirome | Cefpirome may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cefpodoxime | Cefpodoxime may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cefprozil | Cefprozil may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cefradine | Cefradine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Ceftaroline fo | Ceftaroline fosamil may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Ceftazidime | Ceftazidime may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Ceftibuten | The excretion of Trifluridine can be decreased when combined with Ceftibuten. |
| Ceftizoxime | The excretion of Trifluridine can be decreased when combined with Ceftizoxime. |
| Ceftobiprole | Ceftobiprole may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Ceftolozane | Trifluridine may decrease the excretion rate of Ceftolozane which could result in a higher serum level. |
| Ceftriaxone | The excretion of Trifluridine can be decreased when combined with Ceftriaxone. |
| Cefuroxime | Cefuroxime may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Celecoxib | Celecoxib may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cephalexin | The excretion of Trifluridine can be decreased when combined with Cephalexin. |
| Cephaloglycin | Cephaloglycin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Certolizumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Certolizumab pegol. |
| Cetirizine | Cetirizine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cevimeline | Cevimeline may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Chloral hydrate | Trifluridine may decrease the excretion rate of Chloral hydrate which could result in a higher serum level. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Trifluridine. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Trifluridine is combined with Chloramphenicol. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Chloroprocaine. |
| Chloroquine | Trifluridine may decrease the excretion rate of Chloroquine which could result in a higher serum level. |
| Chlorothiazide | Chlorothiazide may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Chlorpromazine | Trifluridine may decrease the excretion rate of Chlorpromazine which could result in a higher serum level. |
| Chlorpropamide | Trifluridine may decrease the excretion rate of Chlorpropamide which could result in a higher serum level. |
| Chlorthalidone | Chlorthalidone may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Chlorzoxazone | Chlorzoxazone may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cholic Acid | The excretion of Trifluridine can be decreased when combined with Cholic Acid. |
| Choline C 11 | Trifluridine may decrease the excretion rate of Choline C 11 which could result in a higher serum level. |
| Choline magnesium | Choline magnesium trisalicylate may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Choline salicylate | Trifluridine may decrease the excretion rate of Choline salicylate which could result in a higher serum level. |
| Chondroitin sul | Trifluridine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level. |
| Chromic chlor | Trifluridine may decrease the excretion rate of Chromic chloride which could result in a higher serum level. |
| Chromic nitrate | Trifluridine may decrease the excretion rate of Chromic nitrate which could result in a higher serum level. |
| Chromium | Trifluridine may decrease the excretion rate of Chromium which could result in a higher serum level. |
| Chromium gluc | Trifluridine may decrease the excretion rate of Chromium gluconate which could result in a higher serum level. |
| Chromium nicotin | Trifluridine may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. |
| Chromous sulfate | Trifluridine may decrease the excretion rate of Chromous sulfate which could result in a higher serum level. |
| Ciclesonide | The risk or severity of adverse effects can be increased when Trifluridine is combined with Ciclesonide. |
| Cidofovir | Cidofovir may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cilastatin | The excretion of Trifluridine can be decreased when combined with Cilastatin. |
| Cilostazol | Trifluridine may decrease the excretion rate of Cilostazol which could result in a higher serum level. |
| Cimetidine | The excretion of Trifluridine can be decreased when combined with Cimetidine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Cinchocaine. |
| Cinoxacin | The excretion of Trifluridine can be decreased when combined with Cinoxacin. |
| Ciprofloxacin | Trifluridine may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level. |
| Cisplatin | The risk or severity of adverse effects can be increased when Trifluridine is combined with Cisplatin. |
| Cladribine | The risk or severity of adverse effects can be increased when Cladribine is combined with Trifluridine. |
| Clevidipine | Trifluridine may decrease the excretion rate of Clevidipine which could result in a higher serum level. |
| Clobazam | Clobazam may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Clobetasol prop | The risk or severity of adverse effects can be increased when Trifluridine is combined with Clobetasol propionate. |
| Clofarabine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Clofarabine. |
| Clomipramine | Trifluridine may decrease the excretion rate of Clomipramine which could result in a higher serum level. |
| Clonazepam | Trifluridine may decrease the excretion rate of Clonazepam which could result in a higher serum level. |
| Clorazepic acid | Trifluridine may decrease the excretion rate of Clorazepic acid which could result in a higher serum level. |
| Clostridium tet | The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trifluridine. |
| Clove oil | Trifluridine may decrease the excretion rate of Clove oil which could result in a higher serum level. |
| Clozapine | Clozapine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Cocaine. |
| Codeine | The excretion of Trifluridine can be decreased when combined with Codeine. |
| Colchicine | Trifluridine may decrease the excretion rate of Colchicine which could result in a higher serum level. |
| Colistimethate | Colistimethate may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Colistin | Trifluridine may decrease the excretion rate of Colistin which could result in a higher serum level. |
| Conivaptan | Conivaptan may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Conjugated estrogens | The excretion of Trifluridine can be decreased when combined with Conjugated estrogens. |
| Corifollitropin alfa | Trifluridine may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level. |
| Corticotropin | The risk or severity of adverse effects can be increased when Trifluridine is combined with Corticotropin. |
| Cortisone acetate | The risk or severity of adverse effects can be increased when Trifluridine is combined with Cortisone acetate. |
| Corynebacterium | The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trifluridine. |
| Cyanocobalamin | Cyanocobalamin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Cyclopenthiazide | Cyclopenthiazide may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Trifluridine is combined with Cyclophosphamide. |
| Cyclosporine | Trifluridine may increase the immunosuppressive activities of Cyclosporine. |
| Cyclothiazide | Cyclothiazide may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Cyproterone acetate | The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Trifluridine. |
| Cytarabine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Cytarabine. |
| Dabigatran etexilate | Trifluridine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level. |
| Dabrafenib | The excretion of Trifluridine can be decreased when combined with Dabrafenib. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Dacarbazine. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Trifluridine is combined with Dactinomycin. |
| Dalfampridine | Trifluridine may decrease the excretion rate of Dalfampridine which could result in a higher serum level. |
| Dapagliflozin | Dapagliflozin may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Daptomycin | Daptomycin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trifluridine. |
| Dasatinib | The risk or severity of adverse effects can be increased when Trifluridine is combined with Dasatinib. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Trifluridine is combined with Daunorubicin. |
| Decitabine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Decitabine. |
| Deferiprone | Trifluridine may decrease the excretion rate of Deferiprone which could result in a higher serum level. |
| Deflazacort | The risk or severity of adverse effects can be increased when Trifluridine is combined with Deflazacort. |
| Delafloxacin | Trifluridine may decrease the excretion rate of Delafloxacin which could result in a higher serum level. |
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Trifluridine. |
| Desipramine | Trifluridine may decrease the excretion rate of Desipramine which could result in a higher serum level. |
| Desmopressin | Desmopressin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Desogestrel | The therapeutic efficacy of Desogestrel can be decreased when used in combination with Trifluridine. |
| Desoximetasone | The risk or severity of adverse effects can be increased when Trifluridine is combined with Desoximetasone. |
| Desvenlafaxine | Trifluridine may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level. |
| Deucravacitinib | The risk or severity of adverse effects can be increased when Trifluridine is combined with Deucravacitinib. |
| Deutetrabenazine | Trifluridine may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level. |
| Dexamethasone | The risk or severity of adverse effects can be increased when Trifluridine is combined with Dexamethasone. |
| Dexibuprofen | Dexibuprofen may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Dexketoprofen | Dexketoprofen may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Dexmedetomidine | Trifluridine may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level. |
| Dexpanthenol | Trifluridine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Trifluridine. |
| Dextran | Trifluridine may decrease the excretion rate of Dextran which could result in a higher serum level. |
| Diatrizoate | Diatrizoate may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Diazepam | Trifluridine may decrease the excretion rate of Diazepam which could result in a higher serum level. |
| Dichlorobenzyl alcohol | Trifluridine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level. |
| Diclofenac | The excretion of Trifluridine can be decreased when combined with Diclofenac. |
| Diclofenamide | Diclofenamide may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Dicyclomine | Trifluridine may decrease the excretion rate of Dicyclomine which could result in a higher serum level. |
| Didanosine | Trifluridine may decrease the excretion rate of Didanosine which could result in a higher serum level. |
| Dienogest | The therapeutic efficacy of Dienogest can be decreased when used in combination with Trifluridine. |
| Diethylstilbestrol | The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Trifluridine. |
| Diflunisal | Diflunisal may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Difluocortolone | The risk or severity of adverse effects can be increased when Trifluridine is combined with Difluocortolone. |
| Digoxin | Trifluridine may decrease the excretion rate of Digoxin which could result in a higher serum level. |
| Dihydrostreptomycin | Dihydrostreptomycin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Dimercaprol | Trifluridine may decrease the excretion rate of Dimercaprol which could result in a higher serum level. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Trifluridine is combined with Dimethyl fumarate. |
| Dimethyl sulfoxide | Trifluridine may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level. |
| Dinoprostone | The excretion of Trifluridine can be decreased when combined with Dinoprostone. |
| Dinutuximab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Dinutuximab. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Diphenhydramine. |
| Diroximel fumarate | The risk or severity of adverse effects can be increased when Trifluridine is combined with Diroximel fumarate. |
| Disopyramide | Disopyramide may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| DL-Methylephedrine | Trifluridine may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level. |
| Dobutamine | Trifluridine may decrease the excretion rate of Dobutamine which could result in a higher serum level. |
| Docetaxel | The risk or severity of adverse effects can be increased when Trifluridine is combined with Docetaxel. |
| Dolutegravir | The excretion of Trifluridine can be decreased when combined with Dolutegravir. |
| Dopamine | Trifluridine may decrease the excretion rate of Dopamine which could result in a higher serum level. |
| Doripenem | Trifluridine may decrease the excretion rate of Doripenem which could result in a higher serum level. |
| Doxacurium | Trifluridine may decrease the excretion rate of Doxacurium which could result in a higher serum level. |
| Doxepin | Trifluridine may decrease the excretion rate of Doxepin which could result in a higher serum level. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Trifluridine is combined with Doxorubicin. |
| Doxycycline | Doxycycline may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Dronedarone | The excretion of Trifluridine can be decreased when combined with Dronedarone. |
| Drospirenone | The therapeutic efficacy of Drospirenone can be decreased when used in combination with Trifluridine. |
| Droxidopa | Trifluridine may decrease the excretion rate of Droxidopa which could result in a higher serum level. |
| Duloxetine | Trifluridine may decrease the excretion rate of Duloxetine which could result in a higher serum level. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Dyclonine. |
| Dyphylline | Trifluridine may decrease the excretion rate of Dyphylline which could result in a higher serum level. |
| Eculizumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Eculizumab. |
| Edoxaban | Trifluridine may decrease the excretion rate of Edoxaban which could result in a higher serum level. |
| Edrophonium | Trifluridine may decrease the excretion rate of Edrophonium which could result in a higher serum level. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Trifluridine. |
| Emapalumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Emapalumab. |
| Enalapril | The excretion of Trifluridine can be decreased when combined with Enalapril. |
| Enalaprilat | Trifluridine may decrease the excretion rate of Enalaprilat which could result in a higher serum level. |
| Enasidenib | The excretion of Trifluridine can be decreased when combined with Enasidenib. |
| Enzalutamide | Trifluridine may decrease the excretion rate of Enzalutamide which could result in a higher serum level. |
| Epirubicin | The risk or severity of adverse effects can be increased when Trifluridine is combined with Epirubicin. |
| Eplerenone | Eplerenone may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Epoprostenol | Trifluridine may decrease the excretion rate of Epoprostenol which could result in a higher serum level. |
| Eribulin | The risk or severity of adverse effects can be increased when Trifluridine is combined with Eribulin. |
| Ertapenem | Ertapenem may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Ertugliflozin | Ertugliflozin may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Trifluridine. |
| Esomeprazole | The excretion of Trifluridine can be decreased when combined with Esomeprazole. |
| Estazolam | Trifluridine may decrease the excretion rate of Estazolam which could result in a higher serum level. |
| Estradiol | The therapeutic efficacy of Estradiol can be decreased when used in combination with Trifluridine. |
| Estradiol acetate | Trifluridine may decrease the excretion rate of Estradiol acetate which could result in a higher serum level. |
| Estradiol benzoate | The therapeutic efficacy of Estradiol benzoate can be decreased when used in combination with Trifluridine. |
| Estradiol cypionate | The therapeutic efficacy of Estradiol cypionate can be decreased when used in combination with Trifluridine. |
| Estradiol dienanthate | Trifluridine may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level. |
| Estradiol valerate | The therapeutic efficacy of Estradiol valerate can be decreased when used in combination with Trifluridine. |
| Estramustine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Estramustine. |
| Estrone sulfate | The therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Trifluridine. |
| Eszopiclone | Eszopiclone may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Etacrynic acid | Etacrynic acid may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Etafedrine | Trifluridine may decrease the excretion rate of Etafedrine which could result in a higher serum level. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Trifluridine. |
| Ethambutol | Ethambutol may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Ethinylestradiol | The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Trifluridine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Ethyl chloride. |
| Ethynodiol diacetate | The therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Trifluridine. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Etidocaine. |
| Etodolac | Etodolac may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Etomidate | Etomidate may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Etonogestrel | The therapeutic efficacy of Etonogestrel can be decreased when used in combination with Trifluridine. |
| Etoposide | The risk or severity of adverse effects can be increased when Trifluridine is combined with Etoposide. |
| Etoricoxib | Etoricoxib may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Eucalyptus oil | Trifluridine may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level. |
| Everolimus | The risk or severity of adverse effects can be increased when Trifluridine is combined with Everolimus. |
| Ezogabine | Trifluridine may decrease the excretion rate of Ezogabine which could result in a higher serum level. |
| Famotidine | The excretion of Trifluridine can be decreased when combined with Famotidine. |
| Famtozinameran | The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Trifluridine. |
| Favipiravir | The excretion of Trifluridine can be decreased when combined with Favipiravir. |
| Fenbufen | Fenbufen may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Fenofibrate | Trifluridine may decrease the excretion rate of Fenofibrate which could result in a higher serum level. |
| Fenofibric acid | Trifluridine may decrease the excretion rate of Fenofibric acid which could result in a higher serum level. |
| Fenoldopam | Trifluridine may decrease the excretion rate of Fenoldopam which could result in a higher serum level. |
| Fenoprofen | Fenoprofen may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Fentanyl | Trifluridine may decrease the excretion rate of Fentanyl which could result in a higher serum level. |
| Fesoterodine | Trifluridine may decrease the excretion rate of Fesoterodine which could result in a higher serum level. |
| Fexinidazole | The excretion of Trifluridine can be decreased when combined with Fexinidazole. |
| Filgotinib | The risk or severity of adverse effects can be increased when Trifluridine is combined with Filgotinib. |
| Finerenone | Finerenone may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Fingolimod | Trifluridine may increase the immunosuppressive activities of Fingolimod. |
| Flavoxate | Trifluridine may decrease the excretion rate of Flavoxate which could result in a higher serum level. |
| Floctafenine | Floctafenine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Florbetaben (18F) | Trifluridine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level. |
| Florbetapir (18F) | Trifluridine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Trifluridine. |
| Fluconazole | Fluconazole may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Flucytosine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Flucytosine. |
| Fludarabine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Fludarabine. |
| Fludeoxyglucose | Trifluridine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Trifluridine is combined with Fludrocortisone. |
| Flumazenil | Trifluridine may decrease the excretion rate of Flumazenil which could result in a higher serum level. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Trifluridine. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluocinolone acetonide. |
| Fluocinonide | The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluocinonide. |
| Fluocortolone | The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluocortolone. |
| Fluorescein | The excretion of Fluorescein can be decreased when combined with Trifluridine. |
| Fluorometholone | The risk or severity of adverse effects can be increased when Fluorometholone is combined with Trifluridine. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluorouracil. |
| Fluprednisolone | The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluprednisolone. |
| Flurazepam | Trifluridine may decrease the excretion rate of Flurazepam which could result in a higher serum level. |
| Flurbiprofen | Flurbiprofen may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Flutamide | Trifluridine may decrease the excretion rate of Flutamide which could result in a higher serum level. |
| Fluticasone | The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluticasone. |
| Fluticasone furoate | The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluticasone furoate. |
| Fluticasone pr | The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluticasone propionate. |
| Fluvoxamine | Fluvoxamine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Folic acid | Folic acid may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Fomepizole | Trifluridine may decrease the excretion rate of Fomepizole which could result in a higher serum level. |
| Fondaparinux | Trifluridine may decrease the excretion rate of Fondaparinux which could result in a higher serum level. |
| Formestane | Trifluridine may decrease the excretion rate of Formestane which could result in a higher serum level. |
| Foscarnet | Foscarnet may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Fosfomycin | Trifluridine may decrease the excretion rate of Fosfomycin which could result in a higher serum level. |
| Fosinopril | Trifluridine may decrease the excretion rate of Fosinopril which could result in a higher serum level. |
| Framycetin | Framycetin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Furosemide | The excretion of Trifluridine can be decreased when combined with Furosemide. |
| Gabapentin en | Trifluridine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. |
| Gadobenic acid | Trifluridine may decrease the excretion rate of Gadobenic acid which could result in a higher serum level. |
| Gadodiamide | Gadodiamide may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Gadofosveset tr | Trifluridine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level. |
| Gadopentetic acid | Trifluridine may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level. |
| Gadoteric acid | Trifluridine may decrease the excretion rate of Gadoteric acid which could result in a higher serum level. |
| Gadoteridol | Trifluridine may decrease the excretion rate of Gadoteridol which could result in a higher serum level. |
| Kanamycin | Trifluridine may decrease the excretion rate of Kanamycin which could result in a higher serum level. |
| Ketamine | Trifluridine may decrease the excretion rate of Ketamine which could result in a higher serum level. |
| Ketazolam | Trifluridine may decrease the excretion rate of Ketazolam which could result in a higher serum level. |
| Ketoprofen | The excretion of Trifluridine can be decreased when combined with Ketoprofen. |
| Ketorolac | Ketorolac may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Labetalol | Trifluridine may decrease the excretion rate of Labetalol which could result in a higher serum level. |
| Lamivudine | Trifluridine may decrease the excretion rate of Lamivudine which could result in a higher serum level. |
| Lamotrigine | Trifluridine may decrease the excretion rate of Lamotrigine which could result in a higher serum level. |
| Lansoprazole | The excretion of Trifluridine can be decreased when combined with Lansoprazole. |
| Latamoxef | Latamoxef may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Ledipasvir | Trifluridine may decrease the excretion rate of Ledipasvir which could result in a higher serum level. |
| Leflunomide | The risk or severity of adverse effects can be increased when Trifluridine is combined with Leflunomide. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Trifluridine is combined with Lenalidomide. |
| Lenvatinib | The excretion of Trifluridine can be decreased when combined with Lenvatinib. |
| Lesinurad | Trifluridine may decrease the excretion rate of Lesinurad which could result in a higher serum level. |
| Letermovir | The excretion of Trifluridine can be decreased when combined with Letermovir. |
| Leucovorin | The excretion of Trifluridine can be decreased when combined with Leucovorin. |
| Leuprolide | Leuprolide may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Levobupivacaine. |
| Levocarnitine | Trifluridine may decrease the excretion rate of Levocarnitine which could result in a higher serum level. |
| Levocetirizine | Trifluridine may decrease the excretion rate of Levocetirizine which could result in a higher serum level. |
| Levofloxacin | Trifluridine may decrease the excretion rate of Levofloxacin which could result in a higher serum level. |
| Levomilnacipran | Trifluridine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level. |
| Levonorgestrel | The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Trifluridine. |
| Levosalbutamol | Trifluridine may decrease the excretion rate of Levosalbutamol which could result in a higher serum level. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Lidocaine. |
| Linezolid | The risk or severity of adverse effects can be increased when Trifluridine is combined with Linezolid. |
| Liothyronine | The excretion of Trifluridine can be decreased when combined with Liothyronine. |
| Liotrix | The excretion of Trifluridine can be decreased when combined with Liotrix. |
| Lisinopril | Trifluridine may decrease the excretion rate of Lisinopril which could result in a higher serum level. |
| Lithium carbonate | Trifluridine may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. |
| Lithium citrate | Lithium citrate may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Lixisenatide | Trifluridine may decrease the excretion rate of Lixisenatide which could result in a higher serum level. |
| Lofexidine | Trifluridine may decrease the excretion rate of Lofexidine which could result in a higher serum level. |
| Lomustine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Lomustine. |
| Lopinavir | The serum concentration of Trifluridine can be increased when it is combined with Lopinavir. |
| Loracarbef | Loracarbef may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Lorazepam | Lorazepam may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Lorcaserin | Trifluridine may decrease the excretion rate of Lorcaserin which could result in a higher serum level. |
| Lornoxicam | Lornoxicam may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Lorpiprazole | Trifluridine may decrease the excretion rate of Lorpiprazole which could result in a higher serum level. |
| Losartan | The excretion of Trifluridine can be decreased when combined with Losartan. |
| Loxoprofen | Loxoprofen may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Lubiprostone | Trifluridine may decrease the excretion rate of Lubiprostone which could result in a higher serum level. |
| Lumiracoxib | Lumiracoxib may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Lynestrenol | The therapeutic efficacy of Lynestrenol can be decreased when used in combination with Trifluridine. |
| Macitentan | Trifluridine may decrease the excretion rate of Macitentan which could result in a higher serum level. |
| Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Trifluridine. |
| Magnesium carb | Trifluridine may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. |
| Magnesium chlor | Trifluridine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level. |
| Magnesium hyd | Trifluridine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. |
| Magnesium tris | Trifluridine may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. |
| Mangafodipir | Trifluridine may decrease the excretion rate of Mangafodipir which could result in a higher serum level. |
| Mannitol | Mannitol may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Maprotiline | Trifluridine may decrease the excretion rate of Maprotiline which could result in a higher serum level. |
| Measles virus vacci | The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Trifluridine. |
| Mecamylamine | Trifluridine may decrease the excretion rate of Mecamylamine which could result in a higher serum level. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Mechlorethamine. |
| Meclofenamic acid | Meclofenamic acid may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Medroxyprogester | The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Trifluridine. |
| Mefenamic acid | Mefenamic acid may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Megestrol acetate | The therapeutic efficacy of Megestrol acetate can be decreased when used in combination with Trifluridine. |
| Melatonin | The excretion of Trifluridine can be decreased when combined with Melatonin. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Meloxicam. |
| Melphalan | The risk or severity of adverse effects can be increased when Trifluridine is combined with Melphalan. |
| Memantine | Trifluridine may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Meningococcal | The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Trifluridine. |
| Meperidine | Trifluridine may decrease the excretion rate of Meperidine which could result in a higher serum level. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Mepivacaine. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Mepolizumab. |
| Meprednisone | The risk or severity of adverse effects can be increased when Trifluridine is combined with Meprednisone. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Mercaptopurine. |
| Meropenem | Trifluridine may decrease the excretion rate of Meropenem which could result in a higher serum level. |
| Mesalazine | Mesalazine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Mestranol | The therapeutic efficacy of Mestranol can be decreased when used in combination with Trifluridine. |
| Metamfetamine | Trifluridine may decrease the excretion rate of Metamfetamine which could result in a higher serum level. |
| Metamizole | Metamizole may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Metaxalone | Trifluridine may decrease the excretion rate of Metaxalone which could result in a higher serum level. |
| Metformin | Metformin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Methadone | Methadone may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Methazolamide | Methazolamide may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Methimazole | The risk or severity of adverse effects can be increased when Trifluridine is combined with Methimazole. |
| Methotrexate | The risk or severity of adverse effects can be increased when Trifluridine is combined with Methotrexate. |
| Methoxsalen | Trifluridine may decrease the excretion rate of Methoxsalen which could result in a higher serum level. |
| Methoxy p | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trifluridine. |
| Methyldopa | Trifluridine may decrease the excretion rate of Methyldopa which could result in a higher serum level. |
| Methylene blue | Trifluridine may decrease the excretion rate of Methylene blue which could result in a higher serum level. |
| Methylnaltrexone | Trifluridine may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Trifluridine is combined with Methylprednisolone. |
| Methyltestosterone | The excretion of Trifluridine can be increased when combined with Methyltestosterone. |
| Meticrane | Meticrane may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Metoclopramide | Trifluridine may decrease the excretion rate of Metoclopramide which could result in a higher serum level. |
| Metolazone | Metolazone may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Metoprolol | Metoprolol may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Metyrapone | Trifluridine may decrease the excretion rate of Metyrapone which could result in a higher serum level. |
| Midazolam | Trifluridine may decrease the excretion rate of Midazolam which could result in a higher serum level. |
| Mifepristone | The therapeutic efficacy of Mifepristone can be decreased when used in combination with Trifluridine. |
| Migalastat | Trifluridine may decrease the excretion rate of Migalastat which could result in a higher serum level. |
| Milnacipran | Trifluridine may decrease the excretion rate of Milnacipran which could result in a higher serum level. |
| Milrinone | Milrinone may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Minocycline | The excretion of Trifluridine can be decreased when combined with Minocycline. |
| Mirabegron | Trifluridine may decrease the excretion rate of Mirabegron which could result in a higher serum level. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Trifluridine. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Trifluridine is combined with Mitoxantrone. |
| MCOVID-19 Vaccine | The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Trifluridine. |
| M vaccinia ankara | The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Trifluridine. |
| Mometasone fu | The risk or severity of adverse effects can be increased when Trifluridine is combined with Mometasone furoate. |
| Monomethyl fum | The risk or severity of adverse effects can be increased when Trifluridine is combined with Monomethyl fumarate. |
| Mosunetuzumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Mosunetuzumab. |
| Moxisylyte | Trifluridine may decrease the excretion rate of Moxisylyte which could result in a higher serum level. |
| Mumps virus | The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Trifluridine. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Trifluridine. |
| Muzolimine | Muzolimine may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Mycophenolate | The risk or severity of adverse effects can be increased when Trifluridine is combined with Mycophenolate mofetil. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Trifluridine is combined with Mycophenolic acid. |
| N-acetyltyrosine | Trifluridine may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level. |
| Nabumetone | Nabumetone may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Nadolol | Trifluridine may decrease the excretion rate of Nadolol which could result in a higher serum level. |
| Nafcillin | The excretion of Trifluridine can be decreased when combined with Nafcillin. |
| Naldemedine | Trifluridine may decrease the excretion rate of Naldemedine which could result in a higher serum level. |
| Nalidixic acid | The excretion of Trifluridine can be decreased when combined with Nalidixic acid. |
| Nalmefene | Trifluridine may decrease the excretion rate of Nalmefene which could result in a higher serum level. |
| Naloxone | Trifluridine may decrease the excretion rate of Naloxone which could result in a higher serum level. |
| Naproxen | Naproxen may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Natalizumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Natalizumab. |
| Nateglinide | Trifluridine may decrease the excretion rate of Nateglinide which could result in a higher serum level. |
| Nedaplatin | Trifluridine may decrease the excretion rate of Nedaplatin which could result in a higher serum level. |
| Nedocromil | Trifluridine may decrease the excretion rate of Nedocromil which could result in a higher serum level. |
| Nefazodone | Trifluridine may decrease the excretion rate of Nefazodone which could result in a higher serum level. |
| Nelarabine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Nelarabine. |
| Neomycin | Trifluridine may decrease the excretion rate of Neomycin which could result in a higher serum level. |
| Netilmicin | Trifluridine may decrease the excretion rate of Netilmicin which could result in a higher serum level. |
| Nicorandil | Trifluridine may decrease the excretion rate of Nicorandil which could result in a higher serum level. |
| Nifedipine | Trifluridine may decrease the excretion rate of Nifedipine which could result in a higher serum level. |
| Nilotinib | The risk or severity of adverse effects can be increased when Trifluridine is combined with Nilotinib. |
| Nilutamide | Trifluridine may decrease the excretion rate of Nilutamide which could result in a higher serum level. |
| Nimesulide | Nimesulide may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Nisoldipine | Nisoldipine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Nitric Oxide | Trifluridine may decrease the excretion rate of Nitric Oxide which could result in a higher serum level. |
| Nitrofurantoin | Trifluridine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. |
| Nitroprusside | Nitroprusside may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Nomegestrol | The therapeutic efficacy of Nomegestrol can be decreased when used in combination with Trifluridine. |
| Nomegestrol | The therapeutic efficacy of Nomegestrol acetate can be decreased when used in combination with Trifluridine. |
| Norelgestromin | The therapeutic efficacy of Norelgestromin can be decreased when used in combination with Trifluridine. |
| Norethisterone | The therapeutic efficacy of Norethisterone can be decreased when used in combination with Trifluridine. |
| Norethynodrel | The therapeutic efficacy of Norethynodrel can be decreased when used in combination with Trifluridine. |
| Norfloxacin | The excretion of Trifluridine can be decreased when combined with Norfloxacin. |
| Norgestimate | The therapeutic efficacy of Norgestimate can be decreased when used in combination with Trifluridine. |
| Norgestrel | The therapeutic efficacy of Norgestrel can be decreased when used in combination with Trifluridine. |
| Novobiocin | The excretion of Trifluridine can be decreased when combined with Novobiocin. |
| Nuvaxovid | The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Trifluridine. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Obinutuzumab. |
| Ocrelizumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Ocrelizumab. |
| Octinoxate | Trifluridine may decrease the excretion rate of Octinoxate which could result in a higher serum level. |
| Ofatumumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Ofatumumab. |
| Ofloxacin | The excretion of Trifluridine can be decreased when combined with Ofloxacin. |
| Olaparib | The risk or severity of adverse effects can be increased when Trifluridine is combined with Olaparib. |
| Olsalazine | Olsalazine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Opium | Trifluridine may decrease the excretion rate of Opium which could result in a higher serum level. |
| Oseltamivir | Oseltamivir may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Ouabain | The excretion of Trifluridine can be decreased when combined with Ouabain. |
| Oxacillin | Trifluridine may decrease the excretion rate of Oxacillin which could result in a higher serum level. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Trifluridine is combined with Oxaliplatin. |
| Oxaprozin | Oxaprozin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Oxazepam | Trifluridine may decrease the excretion rate of Oxazepam which could result in a higher serum level. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Oxetacaine. |
| Oxybenzone | Trifluridine may decrease the excretion rate of Oxybenzone which could result in a higher serum level. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Oxybuprocaine. |
| Oxyphenbutazone | Oxyphenbutazone may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Oxyquinoline | Trifluridine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. |
| Oxytetracycline | The excretion of Trifluridine can be decreased when combined with Oxytetracycline. |
| Ozanimod | The risk or severity of adverse effects can be increased when Trifluridine is combined with Ozanimod. |
| Paclitaxel | The risk or severity of adverse effects can be increased when Trifluridine is combined with Paclitaxel. |
| Palbociclib | The risk or severity of adverse effects can be increased when Trifluridine is combined with Palbociclib. |
| Paliperidone | Trifluridine may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
| Palonosetron | Palonosetron may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Pamidronic acid | Pamidronic acid may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Panobinostat | The risk or severity of adverse effects can be increased when Trifluridine is combined with Panobinostat. |
| Pantoprazole | The excretion of Trifluridine can be decreased when combined with Pantoprazole. |
| Parecoxib | Parecoxib may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Paromomycin | Paromomycin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Patent Blue | Trifluridine may decrease the excretion rate of Patent Blue which could result in a higher serum level. |
| Pazopanib | The risk or severity of adverse effects can be increased when Trifluridine is combined with Pazopanib. |
| Pegaptanib | Trifluridine may decrease the excretion rate of Pegaptanib which could result in a higher serum level. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trifluridine. |
| Pegcetacoplan | The risk or severity of adverse effects can be increased when Trifluridine is combined with Pegcetacoplan. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Trifluridine. |
| Peginterferon al | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Trifluridine. |
| Peginterferon al | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Trifluridine. |
| Peginterferon | The risk or severity of adverse effects can be increased when Trifluridine is combined with Peginterferon beta-1a. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Trifluridine is combined with Pemetrexed. |
| Penbutolol | Trifluridine may decrease the excretion rate of Penbutolol which could result in a higher serum level. |
| Penicillamine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Penicillamine. |
| Pentaerythritol | Trifluridine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level. |
| Pentamidine | Pentamidine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Pentastarch | Trifluridine may decrease the excretion rate of Pentastarch which could result in a higher serum level. |
| Pentetic acid | Trifluridine may decrease the excretion rate of Pentetic acid which could result in a higher serum level. |
| Pentobarbital | Pentobarbital may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Pentostatin | The risk or severity of adverse effects can be increased when Trifluridine is combined with Pentostatin. |
| Pentoxifylline | Trifluridine may decrease the excretion rate of Pentoxifylline which could result in a higher serum level. |
| Perindopril | Trifluridine may decrease the excretion rate of Perindopril which could result in a higher serum level. |
| Permethrin | Trifluridine may decrease the excretion rate of Permethrin which could result in a higher serum level. |
| Pertussis vaccine | The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Trifluridine. |
| Phenazopyridine | Phenazopyridine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Phenelzine | Trifluridine may decrease the excretion rate of Phenelzine which could result in a higher serum level. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Phenol. |
| Phentolamine | Trifluridine may decrease the excretion rate of Phentolamine which could result in a higher serum level. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Trifluridine. |
| Phenylbutazone | The excretion of Trifluridine can be decreased when combined with Phenylbutazone. |
| Pholcodine | Trifluridine may decrease the excretion rate of Pholcodine which could result in a higher serum level. |
| Phosphoric acid | Trifluridine may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. |
| Phylloquinone | Trifluridine may decrease the excretion rate of Phylloquinone which could result in a higher serum level. |
| Picosulfuric acid | Trifluridine may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level. |
| Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trifluridine. |
| Pindolol | Trifluridine may decrease the excretion rate of Pindolol which could result in a higher serum level. |
| Piperacillin | Piperacillin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Piracetam | Trifluridine may decrease the excretion rate of Piracetam which could result in a higher serum level. |
| Piretanide | Piretanide may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Trifluridine is combined with Pirfenidone. |
| Piroxicam | The excretion of Trifluridine can be decreased when combined with Piroxicam. |
| Pirtobrutinib | The risk or severity of adverse effects can be increased when Trifluridine is combined with Pirtobrutinib. |
| Pitolisant | Trifluridine may decrease the excretion rate of Pitolisant which could result in a higher serum level. |
| Plazomicin | Trifluridine may decrease the excretion rate of Plazomicin which could result in a higher serum level. |
| Plerixafor | Trifluridine may decrease the excretion rate of Plerixafor which could result in a higher serum level. |
| Polythiazide | Polythiazide may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Pomalidomide | The risk or severity of adverse effects can be increased when Trifluridine is combined with Pomalidomide. |
| Ponatinib | The risk or severity of adverse effects can be increased when Trifluridine is combined with Ponatinib. |
| Ponesimod | The risk or severity of adverse effects can be increased when Trifluridine is combined with Ponesimod. |
| Potassium | Potassium may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Potassium ac | Trifluridine may decrease the excretion rate of Potassium acetate which could result in a higher serum level. |
| Potassium bic | Trifluridine may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level. |
| Potassium ca | Potassium cation may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Potassium chl | Trifluridine may decrease the excretion rate of Potassium chloride which could result in a higher serum level. |
| Potassium cit | Potassium citrate may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Potassium nitrate | Trifluridine may decrease the excretion rate of Potassium nitrate which could result in a higher serum level. |
| Potassium per | Trifluridine may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level. |
| Potassium sul | Trifluridine may decrease the excretion rate of Potassium sulfate which could result in a higher serum level. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Trifluridine is combined with Pralatrexate. |
| Pralidoxime | Trifluridine may decrease the excretion rate of Pralidoxime which could result in a higher serum level. |
| Pralsetinib | The excretion of Trifluridine can be decreased when combined with Pralsetinib. |
| Pramipexole | Pramipexole may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Pramocaine. |
| Prasugrel | Trifluridine may decrease the excretion rate of Prasugrel which could result in a higher serum level. |
| Pravastatin | The excretion of Trifluridine can be decreased when combined with Pravastatin. |
| Prednisolone | The risk or severity of adverse effects can be increased when Trifluridine is combined with Prednisolone. |
| Prednisone | The risk or severity of adverse effects can be increased when Trifluridine is combined with Prednisone. |
| Pregabalin | Pregabalin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Pretomanid | The serum concentration of Trifluridine can be increased when it is combined with Pretomanid. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Prilocaine. |
| Probenecid | The excretion of Trifluridine can be decreased when combined with Probenecid. |
| Procainamide | Trifluridine may decrease the excretion rate of Procainamide which could result in a higher serum level. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Procaine. |
| Procaine ben | Trifluridine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. |
| Procarbazine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Procarbazine. |
| Progesterone | The therapeutic efficacy of Progesterone can be decreased when used in combination with Trifluridine. |
| Promethazine | Trifluridine may decrease the excretion rate of Promethazine which could result in a higher serum level. |
| Propantheline | Trifluridine may decrease the excretion rate of Propantheline which could result in a higher serum level. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Proparacaine. |
| Propiverine | Trifluridine may decrease the excretion rate of Propiverine which could result in a higher serum level. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Propoxycaine. |
| Propranolol | Trifluridine may decrease the excretion rate of Propranolol which could result in a higher serum level. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Trifluridine is combined with Propylthiouracil. |
| Prucalopride | Trifluridine may decrease the excretion rate of Prucalopride which could result in a higher serum level. |
| Pyrantel | Trifluridine may decrease the excretion rate of Pyrantel which could result in a higher serum level. |
| Pyrazinamide | Pyrazinamide may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Pyridoxine | Pyridoxine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Quetiapine | Trifluridine may decrease the excretion rate of Quetiapine which could result in a higher serum level. |
| Quinethazone | Quinethazone may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Quinidine | Trifluridine may decrease the excretion rate of Quinidine which could result in a higher serum level. |
| Rabeprazole | Trifluridine may decrease the excretion rate of Rabeprazole which could result in a higher serum level. |
| Rabies immune | The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Trifluridine. |
| Rab antigen, A | The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Trifluridine. |
| Ra antigen, B | The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Trifluridine. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Trifluridine. |
| Ramelteon | Trifluridine may decrease the excretion rate of Ramelteon which could result in a higher serum level. |
| Ranitidine | Trifluridine may decrease the excretion rate of Ranitidine which could result in a higher serum level. |
| Ranolazine | Ranolazine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Rasagiline | Trifluridine may decrease the excretion rate of Rasagiline which could result in a higher serum level. |
| Ravulizumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Ravulizumab. |
| Reserpine | Reserpine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Resorcinol | Trifluridine may decrease the excretion rate of Resorcinol which could result in a higher serum level. |
| Ribavirin | Trifluridine may decrease the excretion rate of Ribavirin which could result in a higher serum level. |
| Riboflavin | The excretion of Trifluridine can be decreased when combined with Riboflavin. |
| Ribostamycin | Trifluridine may decrease the excretion rate of Ribostamycin which could result in a higher serum level. |
| Rifampicin | The excretion of Trifluridine can be decreased when combined with Rifampicin. |
| Rilonacept | The risk or severity of adverse effects can be increased when Trifluridine is combined with Rilonacept. |
| Risankizumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Risankizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Trifluridine. |
| Rivaroxaban | Trifluridine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. |
| Rizatriptan | Trifluridine may decrease the excretion rate of Rizatriptan which could result in a higher serum level. |
| Rofecoxib | Rofecoxib may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Roflumilast | Roflumilast may increase the immunosuppressive activities of Trifluridine. |
| Ropeginterferon a | The risk or severity of adverse effects can be increased when Trifluridine is combined with Ropeginterferon alfa-2b. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Ropivacaine. |
| Rosiglitazone | Rosiglitazone may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Rosuvastatin | The excretion of Trifluridine can be decreased when combined with Rosuvastatin. |
| Rotavirus vaccine | The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Trifluridine. |
| Rubella virus vaccine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Trifluridine. |
| Ruxolitinib | The risk or severity of adverse effects can be increased when Trifluridine is combined with Ruxolitinib. |
| Sacubitril | Trifluridine may decrease the excretion rate of Sacubitril which could result in a higher serum level. |
| Salbutamol | Trifluridine may decrease the excretion rate of Salbutamol which could result in a higher serum level. |
| Salicylamide | Salicylamide may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Salicylic acid | The excretion of Trifluridine can be decreased when combined with Salicylic acid. |
| Salmon calci | Salmon calcitonin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Salsalate | Salsalate may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Sarilumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Sarilumab. |
| Satralizumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Satralizumab. |
| Saxagliptin | Trifluridine may decrease the excretion rate of Saxagliptin which could result in a higher serum level. |
| Secobarbital | Secobarbital may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Secukinumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Secukinumab. |
| Selenious acid | Trifluridine may decrease the excretion rate of Selenious acid which could result in a higher serum level. |
| Selenium | Trifluridine may decrease the excretion rate of Selenium which could result in a higher serum level. |
| Sibutramine | Trifluridine may decrease the excretion rate of Sibutramine which could result in a higher serum level. |
| Siltuximab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Siltuximab. |
| Siponimod | The risk or severity of adverse effects can be increased when Trifluridine is combined with Siponimod. |
| Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Trifluridine. |
| Sirolimus | The risk or severity of adverse effects can be increased when Trifluridine is combined with Sirolimus. |
| Sitagliptin | Trifluridine may decrease the excretion rate of Sitagliptin which could result in a higher serum level. |
| Smallpox (Vacc | The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Trifluridine. |
| Sodium acetate | Trifluridine may decrease the excretion rate of Sodium acetate which could result in a higher serum level. |
| Sodium aurothi | Trifluridine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level. |
| Sodium fluoride | Trifluridine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level. |
| Sodium sulfate | Trifluridine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. |
| Sofosbuvir | Trifluridine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. |
| Solriamfetol | Trifluridine may decrease the excretion rate of Solriamfetol which could result in a higher serum level. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Trifluridine. |
| Sorbitol | Trifluridine may decrease the excretion rate of Sorbitol which could result in a higher serum level. |
| Spesolimab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Spesolimab. |
| Spironolactone | Spironolactone may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Stavudine | The excretion of Stavudine can be decreased when combined with Trifluridine. |
| Stiripentol | Trifluridine may decrease the excretion rate of Stiripentol which could result in a higher serum level. |
| Streptomycin | Trifluridine may decrease the excretion rate of Streptomycin which could result in a higher serum level. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Trifluridine. |
| Strontium chloride | Trifluridine may decrease the excretion rate of Strontium chloride which could result in a higher serum level. |
| Sucralfate | Sucralfate may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Sulbactam | Trifluridine may decrease the excretion rate of Sulbactam which could result in a higher serum level. |
| Sulfadiazine | Sulfadiazine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Sulfamethoxazole | The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Trifluridine. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Sulfasalazine. |
| Sulindac | Sulindac may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Sumatriptan | Trifluridine may decrease the excretion rate of Sumatriptan which could result in a higher serum level. |
| Sunitinib | The risk or severity of adverse effects can be increased when Trifluridine is combined with Sunitinib. |
| Sutimlimab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Sutimlimab. |
| Sy Estrogens, A | Trifluridine may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level. |
| Syn Estrogens, B | Trifluridine may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level. |
| Tacrolimus | Tacrolimus may increase the immunosuppressive activities of Trifluridine. |
| Tadalafil | Trifluridine may decrease the excretion rate of Tadalafil which could result in a higher serum level. |
| Tafamidis | The excretion of Trifluridine can be decreased when combined with Tafamidis. |
| Tamsulosin | Trifluridine may decrease the excretion rate of Tamsulosin which could result in a higher serum level. |
| Tasimelteon | Trifluridine may decrease the excretion rate of Tasimelteon which could result in a higher serum level. |
| Taurocholic acid | The excretion of Trifluridine can be decreased when combined with Taurocholic acid. |
| Tazobactam | The excretion of Trifluridine can be decreased when combined with Tazobactam. |
| Technetium T | Trifluridine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level. |
| Technetium Tc | Trifluridine may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level. |
| Technetium | Trifluridine may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level. |
| Technetium | Trifluridine may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. |
| Teduglutide | Trifluridine may decrease the excretion rate of Teduglutide which could result in a higher serum level. |
| Tegafur | Trifluridine may decrease the excretion rate of Tegafur which could result in a higher serum level. |
| Telavancin | Trifluridine may decrease the excretion rate of Telavancin which could result in a higher serum level. |
| Temazepam | Temazepam may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Temozolomide | The risk or severity of adverse effects can be increased when Trifluridine is combined with Temozolomide. |
| Temsirolimus | The risk or severity of adverse effects can be increased when Trifluridine is combined with Temsirolimus. |
| Teniposide | The risk or severity of adverse effects can be increased when Trifluridine is combined with Teniposide. |
| Tenofovir alafenamide | The serum concentration of Tenofovir alafenamide can be increased when it is combined with Trifluridine. |
| Tenofovir disoproxil | Tenofovir disoproxil may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Tenoxicam | The excretion of Trifluridine can be decreased when combined with Tenoxicam. |
| Teprotumumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Teprotumumab. |
| Terbutaline | Trifluridine may decrease the excretion rate of Terbutaline which could result in a higher serum level. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Trifluridine is combined with Teriflunomide. |
| Testolactone | Trifluridine may decrease the excretion rate of Testolactone which could result in a higher serum level. |
| Testosterone | The excretion of Trifluridine can be increased when combined with Testosterone. |
| Testosterone cypi | The excretion of Trifluridine can be increased when combined with Testosterone cypionate. |
| Testosterone ena | The therapeutic efficacy of Testosterone enanthate can be decreased when used in combination with Trifluridine. |
| Testosterone pro | Trifluridine may decrease the excretion rate of Testosterone propionate which could result in a higher serum level. |
| Testosterone und | Trifluridine may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Tetracaine. |
| Tetracycline | The excretion of Trifluridine can be decreased when combined with Tetracycline. |
| Tetradecyl hydr | Trifluridine may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level. |
| Thalidomide | The risk or severity of adverse effects can be increased when Trifluridine is combined with Thalidomide. |
| Thiabendazole | Trifluridine may decrease the excretion rate of Thiabendazole which could result in a higher serum level. |
| Thiethylperazine | Thiethylperazine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Thiotepa | The risk or severity of adverse effects can be increased when Trifluridine is combined with Thiotepa. |
| Tiaprofenic acid | Tiaprofenic acid may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Tick-borne encep | The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Trifluridine. |
| Ticlopidine | Ticlopidine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Tiludronic acid | Trifluridine may decrease the excretion rate of Tiludronic acid which could result in a higher serum level. |
| Timolol | Timolol may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Tinidazole | Trifluridine may decrease the excretion rate of Tinidazole which could result in a higher serum level. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Trifluridine. |
| Tiopronin | Trifluridine may decrease the excretion rate of Tiopronin which could result in a higher serum level. |
| Tiotropium | Trifluridine may decrease the excretion rate of Tiotropium which could result in a higher serum level. |
| Tirofiban | Trifluridine may decrease the excretion rate of Tirofiban which could result in a higher serum level. |
| Tixocortol | The risk or severity of adverse effects can be increased when Trifluridine is combined with Tixocortol. |
| Tobramycin | Trifluridine may decrease the excretion rate of Tobramycin which could result in a higher serum level. |
| Tocilizumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Tocilizumab. |
| Tocopherol | Trifluridine may decrease the excretion rate of Tocopherol which could result in a higher serum level. |
| Tofacitinib | Trifluridine may increase the immunosuppressive activities of Tofacitinib. |
| Tolazamide | Trifluridine may decrease the excretion rate of Tolazamide which could result in a higher serum level. |
| Tolbutamide | Trifluridine may decrease the excretion rate of Tolbutamide which could result in a higher serum level. |
| Tolcapone | Tolcapone may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Tolfenamic acid | Tolfenamic acid may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Tolmetin | Tolmetin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Tolterodine | Trifluridine may decrease the excretion rate of Tolterodine which could result in a higher serum level. |
| Tolvaptan | Tolvaptan may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Topiramate | Topiramate may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Topotecan | The risk or severity of adverse effects can be increased when Trifluridine is combined with Topotecan. |
| Torasemide | Torasemide may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Trifluridine. |
| Trabectedin | The risk or severity of adverse effects can be increased when Trifluridine is combined with Trabectedin. |
| Tramadol | Tramadol may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Trametinib | Trifluridine may decrease the excretion rate of Trametinib which could result in a higher serum level. |
| Trastuzumab | Trastuzumab may increase the neutropenic activities of Trifluridine. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Trastuzumab emtansine. |
| Tretinoin | The risk or severity of adverse effects can be increased when Trifluridine is combined with Tretinoin. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Trifluridine is combined with Triamcinolone. |
| Triamterene | Triamterene may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Triazolam | Trifluridine may decrease the excretion rate of Triazolam which could result in a higher serum level. |
| Trichlormethiazide | Trichlormethiazide may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
| Triethylenetetramine | Trifluridine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level. |
| Trilostane | The risk or severity of adverse effects can be increased when Trifluridine is combined with Trilostane. |
| Trimebutine | Trifluridine may decrease the excretion rate of Trimebutine which could result in a higher serum level. |
| Trimethoprim | Trifluridine may decrease the excretion rate of Trimethoprim which could result in a higher serum level. |
| Trimetrexate | Trifluridine may decrease the excretion rate of Trimetrexate which could result in a higher serum level. |
| Tropisetron | Trifluridine may decrease the excretion rate of Tropisetron which could result in a higher serum level. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Trifluridine. |
| Typhoid Vaccine | The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Trifluridine. |
| Typhoid Vi poly | The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Trifluridine. |
| Ublituximab | The risk or severity of infection can be increased when Ublituximab is combined with Trifluridine. |
| Ulipristal | The therapeutic efficacy of Ulipristal can be decreased when used in combination with Trifluridine. |
| Upadacitinib | The risk or severity of adverse effects can be increased when Trifluridine is combined with Upadacitinib. |
| Vaborbactam | Trifluridine may decrease the excretion rate of Vaborbactam which could result in a higher serum level. |
| Valaciclovir | Valaciclovir may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Valbenazine | Trifluridine may decrease the excretion rate of Valbenazine which could result in a higher serum level. |
| Valdecoxib | Valdecoxib may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Valganciclovir | Trifluridine may decrease the excretion rate of Valganciclovir which could result in a higher serum level. |
| Valproic acid | The excretion of Trifluridine can be decreased when combined with Valproic acid. |
| Vancomycin | Trifluridine may decrease the excretion rate of Vancomycin which could result in a higher serum level. |
| Varenicline | Trifluridine may decrease the excretion rate of Varenicline which could result in a higher serum level. |
| Varicella zoster vac | The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Trifluridine. |
| Varicella zoster va | The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Trifluridine. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Trifluridine is combined with Vedolizumab. |
| Venlafaxine | Venlafaxine may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
| Verapamil | Trifluridine may decrease the excretion rate of Verapamil which could result in a higher serum level. |
| Vibrio live antigen | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Trifluridine. |
| Vilanterol | The risk or severity of adverse effects can be increased when Trifluridine is combined with Vilanterol. |
| Viloxazine | Trifluridine may decrease the excretion rate of Viloxazine which could result in a higher serum level. |
| Vinblastine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Vinblastine. |
| Vincristine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Vincristine. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Trifluridine. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Trifluridine. |
| Voclosporin | The risk or severity of adverse effects can be increased when Trifluridine is combined with Voclosporin. |
| Vorinostat | The risk or severity of adverse effects can be increased when Trifluridine is combined with Vorinostat. |
| Vortioxetine | Trifluridine may decrease the excretion rate of Vortioxetine which could result in a higher serum level. |
| Warfarin | Trifluridine may decrease the excretion rate of Warfarin which could result in a higher serum level. |
| Yellow fever va | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Trifluridine. |
| Zalcitabine | The excretion of Zalcitabine can be decreased when combined with Trifluridine. |
| Zaleplon | Trifluridine may decrease the excretion rate of Zaleplon which could result in a higher serum level. |
| Zanamivir | Trifluridine may decrease the excretion rate of Zanamivir which could result in a higher serum level. |
| Zidovudine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Zidovudine. |
| Zonisamide | Zonisamide may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy. |
Pregnancy and Lactation
FDA pregnancy risk category C
Pregnancy
There are no adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic or fetotoxic effects were observed in rabbits following ophthalmic administration of doses approximately 5 times the estimated human exposure. However, offspring of rats and rabbits receiving subcutaneous doses of 2.5—5 mg/kg/day (11.5—23 times the estimated human exposure) experienced toxicities that included delayed ossification, fetal death, and resorption. While systemic absorption following ophthalmic administration is minimal, do not use or prescribed in pregnant women unless clearly needed.
Lactation
Trifluridine is not likely to be excreted in the breast milk after ophthalmic administration due to its relatively small dosage, its dilution in body fluids, and its extremely short half-life. According to the manufacturer, it should not be prescribed for nursing mothers unless the potential benefits outweigh the potential risks. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA.
Why is this medication prescribed?
The combination of trifluridine and tipiracil is used to treat colon (large intestine) or rectal cancer that has spread to other parts of the body in people who have already been treated with other chemotherapy medications or cannot receive these chemotherapy medications. The combination of trifluridine and tipiracil is also used to treat certain types of stomach cancer or cancer located in the area where the stomach meets the esophagus (the tube between the throat and stomach) that has spread to other parts of the body in people who have already received at least two other chemotherapy treatments. Trifluridine is in a class of medications called thymidine-based nucleoside analogues. It works by stopping the growth of cancer cells. Tipiracil is in a class of medications called thymidine phosphorylase inhibitors. It works by slowing the breakdown of trifluridine by the body.
How should this medicine be used?
The combination of trifluridine and tipiracil comes as a tablet to take by mouth. It is usually taken twice a day with food for 5 days in a row, followed by a 2-day break. This dosing schedule is repeated and then followed by a 2-week break. This 28-day cycle may be repeated depending on how well this medication works for you and the side effects you experience. Take trifluridine and tipiracil at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take trifluridine and tipiracil exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Swallow the tablets whole; do not split, chew, or crush them.
Trifluridine and tipiracil tablets come in two different strengths. Your doctor may want you to take a combination of both strengths of tablets to make up your full dose. Be sure that you know what each type of tablet looks like and how many you are to take of each. Ask your doctor or pharmacist if you have any questions.
Your doctor may delay your treatment or decrease your dose of trifluridine and tipiracil depending on the side effects that you experience. Be sure to talk to your doctor about how you are feeling during your treatment. Do not stop taking trifluridine and tipiracil without talking to your doctor.
Wash your hands after handling trifluridine and tipiracil tablets. If someone else is handling your trifluridine and tipiracil tablets, they should wear rubber or latex gloves so that their skin does not come into contact with the tablets. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What special precautions should I follow?
Before taking trifluridine and tipiracil,
- tell your doctor and pharmacist if you are allergic to trifluridine and tipiracil, any other medications, or any of the ingredients in trifluridine and tipiracil tablets. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take.
- tell your doctor if you are 65 years of age or older, or have or have ever had liver or kidney disease.
- tell your doctor if you are pregnant, plan to become pregnant, or if you plan to father a child. You or your partner should not become pregnant during your treatment with trifluridine and tipiracil. If you are female, you will need to have a pregnancy test before you start treatment, and you should use birth control to prevent pregnancy during your treatment and for 6 months after your final dose. Talk to your doctor about birth control methods that you can use during your treatment. If you are a man and your partner can become pregnant, you should use a condom while taking this medication, and for 3 months after your treatment. If you or your partner become pregnant while you are receiving trifluridine and tipiracil, call your doctor immediately. Trifluridine and tipiracil may harm the fetus.
- tell your doctor if you are breastfeeding. Your doctor will probably tell you not to breastfeed during your treatment and for 1 day after your last dose.
What should I do if I forget a dose?
If you miss a dose of trifluridine and tipiracil, do not take another dose to make up for the missed dose. Call your doctor for instructions about what to do for a missed dose.
References
